Navigation Links
Bayer's Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone
Date:6/5/2011

s study and will offer patients in the placebo arm treatment with radium-223 chloride.

Phase III Trial Design

The ALSYMPCA trial is a Phase III, randomized (2:1), double-blind, multi-dose, placebo-controlled international study of radium-223 chloride plus current standard of care compared with placebo plus current standard of care in patients with symptomatic castration-resistant/hormone-refractory prostate cancer that has spread to the bone.  The primary endpoint of the study is overall survival.  Secondary endpoints include time to occurrence of skeletal related events (SRE), changes and time to progression in prostate-specific antigen (PSA) tests and alkaline phosphatase (ALP) tests, safety and impact on quality of life and health economics.  ALSYMPCA was initiated by Algeta ASA (Oslo, Norway) in June 2008.  Enrollment in the trial was completed in January 2011 and 922 patients were randomized.  

About Radium-223 Chloride

Radium-223 chloride is an investigational pharmaceutical containing an alpha-particle emitting nuclide in development for cancer patients with bone metastases.  In September 2009, Bayer signed an agreement with Algeta ASA (Oslo, Norway) for the development and commercialization of radium-223 chloride.  Under the terms of the agreement, Bayer will develop, apply for global health authority approvals, and commercialize radium-223 chloride globally, while Algeta retains an option for up to 50/50 co-promotion and profit-sharing in the United States.  

About CRPC and Bone Metastases

Prostate cancer is the most common cancer among men in Northern European countries and the United States. In 2008, an estimated 903,000 men had prostate cancer and 250,000 died from the disease worldwide.

Castration-resistant prostate cancer (CRPC) was formerly known as hormone-refractory prostate cancer (HRPC).  Approximately 90 percent of men with CR
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC
2. Bayer to Present Data on Investigational Oncology Compounds at 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)
3. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
4. Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control in Patients with Lipodystrophy
5. Investigational Drug May Reduce Involuntary Movements in People With Parkinsons Disease
6. Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710
7. Positive Phase 2 Results Reported with Boehringer Ingelheims Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients
8. FDA Accepts Investigational New Drug Application for ARI-3030MO; First in Man Clinical Trial to Begin During First Quarter of 2011
9. Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
10. Lilly Marks Major Milestone for Mirror Portfolio with Agreement by Independent Fund to License First Two Investigational Medicines
11. FDA Grants Orphan Drug Designation to Bayers Investigational Compound Regorafenib for the Treatment of Gastrointestinal Stromal Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Utah , July 10, 2014  BC Technical, ... and MiE America , Inc., a leading provider ... entered into a long-term agreement naming BC Technical as ... US. MiE and BC Technical announced ... agreement to establish BC Technical as the service and ...
(Date:7/10/2014)... WOONSOCKET, R.I. , July 10, 2014 CVS ... its board of directors has approved a quarterly dividend of ... The dividend is payable on August 1, 2014, to holders ... Caremark CVS Caremark is dedicated to helping ... integrated pharmacy company in the United States ...
(Date:1/15/2014)... Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... used on patients in order to treat dental impairments, ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3
... Median time to pain progression is 66.1 weeks ... the placebo arm --,Hazard ratio of 0.64 (95% ... relative risk of pain progression, MARTINSRIED/MUNICH, Germany, May ... -- GPC Biotech AG and,Pharmion Corporation today announced ...
... analysis shows nearly nine out of ten patients ... of 12 months, WASHINGTON, D.C., May 22, 2007 ... extension study (303),presented at the British Society of ... showed Shire plc's,Lialda(mesalamine) is well tolerated in mild ...
Cached Medicine Technology:Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 2Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 3Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 4Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 5Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 6Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 2Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 3Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 4Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 5Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 6Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 7Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 8
(Date:7/11/2014)... According to a new market research ... Communication Technology (ZigBee, Z-Wave, Bluetooth, Wi-Fi, NFC, RFID), Application ... Transportation, Agriculture) & Geography - Global Trends & Forecasts ... Things market was worth $1029.5 Billion in 2013, and ... an estimated CAGR of 4.08% from 2014 to 2020. ...
(Date:7/11/2014)... As reported by the New ... a significant number of severe adverse events such as ... even death from the highly-promoted and costly immune-system drug, ... report , a regulatory filing revealed that the ... was almost 14% of prescriptions, up from 9.1% in ...
(Date:7/11/2014)... New York, NY (PRWEB) July 11, 2014 ... growth during the five years to 2014 on the ... Regulations of 2010 prompted farmers to dedicate a larger ... in ethanol production. More specifically, the regulations required the ... Similarly, rapidly expanding biofuel production in the United States ...
(Date:7/11/2014)... 11, 2014 Ticket Down is a reliable source ... Mountain View, CA. Over the years Luke Bryan has been ... only does he do well at award shows, but each summer, ... most anticipated tours of the genre and this summer is more ... can compare to the popularity and success that is currently entitled ...
(Date:7/11/2014)... Europe is one of the largest consumers of ... land area. The agricultural sector is a significant user ... of the total water use. The scale and importance ... but far from negligible in most northern ones. , ... of the water use in most countries, while in ...
Breaking Medicine News(10 mins):Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 2Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 3Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 2Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 3
... in ... underserved areas, WOODLAND HILLS, Calif., Dec. 11 ... in end of,year donations to various food banks throughout California. An unrestricted,check ... California to assist vulnerable populations., Blue Cross employees will visit each ...
... EntreMed, Inc.,(Nasdaq: ENMD ), a clinical-stage ... cancer and inflammatory diseases, today,announced that the ... accepted its,Investigational New Drug (IND) application for ... (Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ), ...
... WARSAW, Ind., Dec. 11 Zimmer Holdings, Inc.,(NYSE: ... industry, announced,today that its Premarket Approval (PMA) application for ... the Food and Drug,Administration., "A number of orthopaedic ... be one of only two companies that can offer ...
... Recent developments regarding,North Carolina,s organ and tissue donation ... to hire Corder Philips to aid in the,campaign ... developments include a grant received from the License ... update their online,registry and increase outreach efforts by ...
... Calif., Dec. 11 Varian Medical,Systems (NYSE: VAR ... the company,s Annual Meeting of Stockholders for February 14,2008 ... meeting will be held at,the Sheraton Palo Alto, 625 ... The meeting will be webcast by CCBN and ...
... regions activated by beliefs and human feelings, study shows ... disbelief and uncertainty activate distinct areas of the brain, ... online in the Annals of Neurology . ... was monitored using functional magnetci resonance imaging (fMRI) while ...
Cached Medicine News:Health News:Blue Cross of California Gives $30,000 in Holiday Donations to Food Banks Throughout the State 2Health News:EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis 2Health News:EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis 3Health News:EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis 4Health News:Zimmer Holdings Receives FDA Approval to Market Mobile Bearing Knee 2Health News:Zimmer Holdings Receives FDA Approval to Market Mobile Bearing Knee 3Health News:Zimmer Holdings Receives FDA Approval to Market Mobile Bearing Knee 4Health News:North Carolina Coalition on Donation Selects Corder Philips for Newest Campaign 2Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:Personal Convictions May Control Both Behavior and Emotions 2
... an innovative, quick and easy automated ... 60% less space on your laboratory ... this amazingly easy-to-use, one-hand system, you ... whole range of Diamond Tips. All ...
200 L, Racked, Pre-sterilized, 96 tips/rack, clear Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....
MBP's equivalent to the "Universal Yellow" tip, this 200 L tip utilizes a MicroPoint design for accurate sample handling. 10 L Ref. mark....
For the quantitative determination of luteinizing hormone (LH) concentration in human serum....
Medicine Products: